IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials

基于序列的测定来量化具有复制能力的HIV储库：尽管有有效的抗逆转录病毒治疗（ART），但HIV-1在所有感染个体中作为长寿命记忆性CD 4 + T细胞内的前病毒DNA持续存在。这种具有复制能力的HIV储库构成了治愈HIV感染的主要屏障。该计划的总体目标是开发和商业化基于序列的HIV储库检测，用于临床HIV治疗干预。具体而言，该检测试剂盒应设计为一种分析工具，用于监测临床研究中可复制HIV库的大小，如果成功，则用于前瞻性临床试验。

Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir: Despite effective antiretroviral therapy (ART), HIV-1 persists in all infected individuals as proviral DNA within long-lived memory CD4+ T cells. This replication-competent HIV reservoir constitutes the primary barrier for curing HIV infection. The overall goal of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. Specifically, the assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and if successful, in prospective clinical trials.